Schedule 13G ownership disclosure
Keros Therapeutics Inc
Common Stock, $0.0001 par value per share · CUSIP: 492327101
Event date: 2025-03-31
- Filing-level shares
- 2,587,146.0
- Percent of class
- 6.3%
- JPMORGAN CHASE & CO.
Shares: 2,587,146.0 · Class: 6.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000019617-25-000427
- Form type
- SCHEDULE 13G
- Filer
- JPMORGAN CHASE & CO
- CIK
- CIK 19617
- Filed
- May 02, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership